



For Immediate Release

CONTACT: Caroline Hardy
602-224-5500
hardyc@ProvistaLS.com
www.ProvistaLS.com

**PROVISTA LIFE SCIENCES (PLS) AND INTERNATIONAL HEALTH TECHNOLOGY (IHT)
ANNOUNCE AGREEMENT TO MARKET AND SELL PROVISTA'S BT TEST® FOR BREAST CANCER**

"The BT Test is a blood test directly associated with the underlying pathology of breast cancer."

Phoenix (June 25, 2008) – Provista Life Sciences LLC (PLS) today announced that it has reached a strategic partnering agreement with International Health Technology to release the company's BT Test into the United Kingdom (UK) and Ireland. The BT Test, a new blood test to aid healthcare providers in early breast cancer detection will be provided through IHT's women's clinic for breast health, BreastHealth UK. PLS and IHT will introduce the BT Test into the UK and Ireland beginning this summer with a following expanded release to other European Union countries thereafter. Terms and conditions for the licensing agreement were not disclosed.

International studies related to the limitations associated with mammography are well documented and support the fact that reliance on mammograms alone leads to both high levels of false negative results and extremely high levels of false positive results. BreastHealth UK assists women in the proactive management of their own breast health needs. The company provides breast screening using state of the art technology and recognized experts in breast disease to identifying breast cancer early. The BT Test compliments the clinics' current programs to assist in the early detection of this devastating disease.

"The BT Test is an analytical tool that is based on a patient's blood chemistry and is directly associated with the underlying pathology of breast cancer," said William Gartner, President and Chief Executive Officer (CEO) of Provista Life Sciences. "Partnering with IHT and their BreastHealth UK clinics allows us to expand the availability of the BT Test to women and physicians in the UK and other EU countries."

The BT Test, or Biomarker Translation Test, finds multiple cancer-related proteins in the blood and combines the results with the patient's medical profile to help physicians in their efforts to find breast cancer as early as possible. Clinical research conducted on the BT Test showed an accuracy rate above 80 percent for all women. When used in conjunction with mammography and other diagnostic imaging procedures, the BT Test offers women the most comprehensive and cost effective means to screen for breast cancer available today.

"Our partnership with PLS allows us to offer the women in the UK and Ireland quick and easy access to this breakthrough test for aiding in the early detection of breast cancer and supports our BreastHealth UK personalized services surrounding overall breast health care," said Troels Jordansen, Director of International Health Technology. "The BT Test is an extremely important advancement in women's healthcare and we are pleased to be partnering with Provista on the international launch of this test."

About Provista Life Sciences

Provista Life Sciences is a biotechnology diagnostics development and commercialization company that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company's Web site at www.ProvistaLS.com or call 001 + 602.224.5500.

About International Health Technology

International Health Technology provides personalized breast screening programs in the UK through BreastHealth UK using state of the art technology and recognized experts in breast disease detection, management and care. For more information, visit the company's Web site at www.breasthealthuk.com or call 011+ 44.1223. 352200